首页> 外文会议>International Conference on Nanoscience and Nanotechnology >Enhanced oral cefotaxime sodium bioavailability after administration of cefotaxime-loaded Eudragit S100 nanoparticles and its influence on the lymphatic transport
【24h】

Enhanced oral cefotaxime sodium bioavailability after administration of cefotaxime-loaded Eudragit S100 nanoparticles and its influence on the lymphatic transport

机译:在施用头孢囊加载的Eudragit S100纳米粒子后增强口服头孢噻肟钠生物利用度及其对淋巴输送的影响

获取原文

摘要

The primary objective of this project was to develop orally active cefotaxime sodium (CS) in Eudragit S100 polymer using a pH-sensitive nanoprecipitation method. An aqueous dispersion of the particles was administered orally to fasted Sprague-Dawley (SD) rats against control. Plasma concentrations and pharmacokinetic parameters within 6h post-dosing were better for the nanoparticles. To evaluate the lymphatic targeting ability, CS nanoparticles were administered in the stomach and compared against an aqueous suspension of free drug. Comparison of the CS concentration detected simultaneously in intestinal lymph with the one detected in plasma revealed that the produced CS nanoparticles promoted the lymphatic transport of CS in the intestinal lymph.
机译:该项目的主要目的是使用pH敏感的纳米沉淀方法在Eudragit S100聚合物中开发口服活性小吃钠(CS)。将颗粒的水分散体口服给予捕获的Sprague-Dawley(SD)大鼠免受对照。在给药后6小时后的血浆浓度和药代动力学参数对于纳米颗粒更好。为了评估淋巴靶向能力,将Cs纳米颗粒在胃中施用并与游离药物的水性悬浮液进行比较。在血浆中检测到的肠淋巴中同时检测到的Cs浓度的比较显示,所产生的Cs纳米颗粒在肠淋巴中促进Cs的淋巴迁移。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号